SLU-PP-332
Synthetic pan-ERR agonist (estrogen-related receptor α/β/γ)
- Class
- Exercise mimetic
- Half-life
- Not established
- Route
- —
- Cadence
- —
- Evidence
- Animal data primarily
Overview
SLU-PP-332 is a synthetic small molecule that activates estrogen-related receptors — orphan nuclear receptors that control how cells make and use energy. It's being researched as an 'exercise mimetic' because it turns on some of the same genes that aerobic exercise does, at least in mice. In those animal studies it increased mitochondrial density in muscle, shifted muscle fibers toward oxidative (endurance) types, and improved running endurance without any actual training.
The metabolic effects in obese mice were striking: diet-induced obese animals given 50 mg/kg twice daily for 28 days lost significant fat mass, burned more fat for fuel, and showed better glucose handling — all without eating less. That's the hook that's driven interest in the research-peptide market, even though SLU-PP-332 isn't actually a peptide (it's a small synthetic molecule) and has never been tested in a human.
Right now this compound exists only in rodent studies and grey-market research-chemical suppliers. No human clinical trial has been completed or published. The preclinical safety profile in mice shows no major red flags at the doses tested, but translating those doses to humans is non-trivial, and the long-term effects — especially on the heart, given that ERRα is heavily expressed in cardiac tissue — are completely unknown in people.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved for human use anywhere. The compound on the research market is unregulated — purity, identity, and actual content vary wildly between suppliers.
- No human safety data. All published studies are in mice. The safety profile in people — dosing, side effects, drug interactions — is completely uncharacterised.
- Cardiovascular unknowns: ERRα is highly expressed in the heart. Mouse studies showed improved cardiac mitochondrial function and some benefit in heart-failure models, but chronic agonism in humans could carry rhythm or remodeling risks that wouldn't surface in 28-day rodent studies.
+ 2 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching SLU-PP-332.
- Body composition (lean mass vs fat mass — the mouse data showed fat loss without reported muscle loss, but human effects unknown)
- Resting heart rate and cardiovascular telemetry (ERRα is highly expressed in cardiac tissue; mouse studies showed increased cardiac mitochondrial function, but chronic effects on heart rate and rhythm in humans untested)
- Fasting glucose and insulin sensitivity markers
- Subjective exercise capacity and endurance
- Hepatic function (AST, ALT — ERRα modulates liver lipid metabolism)
Frequently asked questions
What is SLU-PP-332?
Synthetic pan-ERR agonist (estrogen-related receptor α/β/γ). SLU-PP-332 is a synthetic small molecule that activates estrogen-related receptors — orphan nuclear receptors that control how cells make and use energy. It's being researched as an 'exercise mimetic' because it turns on some of the same genes that aerobic exercise does, at least in mice. In those animal studies it increased mitochondrial density in muscle, shifted muscle fibers toward oxidative (endurance) types, and improved running endurance without any actual training.
What is the half-life of SLU-PP-332?
Not established — Pharmacokinetic data in humans not available; preclinical studies used twice-daily IP dosing.
Is SLU-PP-332 approved for human use?
SLU-PP-332 is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for SLU-PP-332?
Evidence tier: Animal data primarily. Billon et al. 2023 (bioRxiv, later published in J. Biol. Chem. 2025) dosed C57BL/6J mice at 50 mg/kg IP twice daily for 28 days. Sedentary mice showed increased running capacity (~25% improvement in time to exhaustion), increased mitochondrial gene expression (SDH-positive fibers), and capillary density in skeletal muscle.
What is commonly monitored when researching SLU-PP-332?
Commonly tracked markers + signals: Body composition (lean mass vs fat mass — the mouse data showed fat loss without reported muscle loss, but human effects unknown), Resting heart rate and cardiovascular telemetry (ERRα is highly expressed in cardiac tissue; mouse studies showed increased cardiac mitochondrial function, but chronic effects on heart rate and rhythm in humans untested), Fasting glucose and insulin sensitivity markers, Subjective exercise capacity and endurance, Hepatic function (AST, ALT — ERRα modulates liver lipid metabolism).
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.